Subclinical hypothyroidism and suicidal behavior: Clinical relevance in psychiatric practice

Subclinical hypothyroidism (SCH), defined by elevated thyroid-stimulating hormone with normal free thyroxine, is traditionally regarded as a clinically silent and benign endocrine state. This assumption, however, is increasingly challenged in psychiatric populations, where even subtle neuroendocrine disturbances may exert significant effects on mood regulation, cognition, stress responsivity, and suicidal behavior. Individuals with mental illness represent a biologically vulnerable group characterized by hypothalamic–pituitary–adrenal axis dysregulation, systemic inflammation, circadian disruption, autoimmune activation, and exposure to psychotropic medications, factors that may amplify the neuropsychiatric impact of mild thyroid dysfunction. Emerging epidemiological and clinical evidence links SCH and autoimmune thyroid disease with depression severity, treatment resistance, and increased suicidal behavior, particularly among adolescents and young adults. In India, where thyroid disorders are highly prevalent and suicide remains a major public health concern, thyroid reference intervals are largely derived from Western populations and are not validated against psychiatric outcomes. This viewpoint argues that SCH is not clinically silent in psychiatric illness and proposes a shift from population-based laboratory cutoffs toward outcome-anchored, context-specific thyroid interpretation. Recalibrating thyroid assessment using suicidality and psychiatric severity as meaningful endpoints may enhance early biological risk detection, support precision psychiatry, and contribute to suicide prevention strategies in resource-constrained settings.